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Activated endothelial cells are capable of assembling three-
dimensional multicellular structures known as capillary beds in
response to several different classes of regulatory macromole-
cules. Understanding the regulatory pathways that control growth
and regression of new blood vessels is a major goal of researchers
in vascular biology today. Regulation of vascular morphogenesis
in endothelial cells can be exerted at the levels of cell-cell
adhesion, cell-matrix interaction, and control of the cell cycle. The
process of angiogenesis, that is, the sprouting of new vessels from
a parent microvessel, encompasses various sequential but often
coincident stages (Fig. 1). Both angiogenic and anti-angiogenic
factors, some of which are listed in Table 1, are believed to target
one or more of the stages [1—6]. Thus, regulation of angiogenesis
is a dynamic process determined by the balance between counter-
acting regulatory factors.
The most prominent positive regulators of angiogenesis, vascu-
lar endothelial growth factor/vascular permeability factor (VEGF/
VPF) and basic fibroblast growth factor (bFGF or FGF2), signal
directly to endothelial cells through their specific receptors,
whereas others (PDGF, TGF-/3, and IGF-1) appear to involve
indirect mechanisms [1, 2, 7—9]. The mode of action of angiogen-
esis inhibitors includes cell cycle arrest (platelet factor-4) [10],
inhibition of signal transduction by growth factors (16 kDa
prolactin) [11], and/or abrogation of bFGF signaling by truncated
high-affinity receptors for bFGF in the circulation and in the
basement membrane of some endothelial cells [12]. Recently, a
newly-defined class of regulatory macromolecules known as ma-
tricellular proteins has received considerable attention, since two
of its members (SPARC and thrombospondin 1) have been shown
to modulate angiogenesis [6, 13—15]. By definition, these secreted
proteins interact with cell-surface receptors, growth factors, and
matrix proteins but do not function as structural matrix compo-
nents. One of the hallmarks of glycoproteins belonging to this
group is their ability to disrupt cell-matrix interactions [16, 17].
SPARC can be considered as a prototype for this class of
counteradhesive proteins that appear to play dynamic roles in
tissue remodeling during normal development or in response to
injury.
SPARC (secreted protein acidic and rich in cysteine), also
known as BM-40, osteonectin, and 43 K protein, is comprised of
four distinct structural domains based on the predicted secondary
structure (Fig. 2) [14, 16, 17]. Of particular interest is our finding
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that a highly conserved, plasmin-sensitive, copper-binding motif
Lys-Gly-His-Lys (KGHK) of SPARC domain II stimulated angio-
genesis in the chick chorioallantoic membrane (CAM) assay in a
concentration-dependent manner (Fig. 3), whereas intact SPARC
displayed a null or anti-angiogenic activity [18, 19]. Consistent
with this finding is the spatial and temporal restriction of SPARC
expression to sites of growing capillaries in the CAM (Fig. 4), with
coincident increases in SPARC proteolysis [19]. In contrast to the
growth-promoting properties of the KGHK motif, a cationic
region of domain II and a Ca2-binding EF-hand region of
domain IV mimicked the activity of native SPARC and inhibited
DNA synthesis by the arrest of endothelial cells in the GI phase
of the cell cycle [20—22].
SPARC can also regulate cell proliferation indirectly by binding
to cytokines. It was shown to interact specifically with the PDGF-
B-chain and abrogate binding of PDGF-AB and -BB to their
receptors on fibroblasts [23]. Through an apparently different
mechanism, SPARC inhibits the mitogenic and chemotactic ef-
fects of bFGF on bovine aortic endothelial cells in vitro [24]. Our
recent results suggest that VEGF-induced proliferation of bovine
and human endothelial cells in vitro can be inhibited by SPARC
and SPARC peptides from domains II and IV in a concentration-
dependent manner by specific binding to VEGF and competition
of the binding of VEGF to its receptors (C. Kupprion, E.H. Sage,
manuscript in preparation). Whether interaction of SPARC with
VEGF can affect vascular morphogenesis is currently being
addressed in our laboratory by quantification of the effect of
SPARC on VEGF-stimulated angiogenesis (P. Parsons-Wing-
erter, C. Kupprion, and E.H. Sage, manuscript in preparation).
As a counteradhesive protein, SPARC mediates cell shape
changes by disrupting focal adhesions, redistributing actin fila-
ments, inhibiting cell spreading, and inducing cell rounding [14,
Table 1. Proteins and peptides regulating angiogenesis
Angiogenic factors Anti-angiogenic factors
SPARC (KGHK motif) SPARC (domains II and IV)
Platelet-derived growth factor Angiostatin
Vascular endothelial growth factor Platelet factor 4
Acidic and basic fibroblast growth factor 16 kDa prolactin
Insulin-like growth factor Thrombospondin-1
Interleukin 8 Interleukin 12
Hcpatocyte growth factor (scatter factor) Interferon a, j3
Transforming growth factor-1
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Fig. 1. The process of angiogenesis. The various
stages of the formation of a capillary sprout
from a pre-existing microvessel are numbered.
These stages are not necessarily sequential.
Basement membrane is shown as a thick black
line, and the interstitium is the stippled area
surrounding the sprout (Drawing provided by
R. Vernon, University of Washington, and
partially adapted from [5]. Reprinted with
permission from Advances in Oncology, 12(2):
17—29, 1996 and Cliggott Publishing Co.).
NH2 4iiIiN'.I4XXXXXXXXXXXX
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Fig. 2. Schematic representation of the murine SPARC protein. Structural domains are highlighted by boxes. Collagen TV-binding domain III and
high-affinity calcium-binding domain IV were recently shown to form a single autonomously folding and crystallizable module known as the PC
(extracellular calcium-binding) domain [291.
Fig. 3. Concentration dependency of the angiogenic activity of the KGHK motif Vitrogen (native type I collagen) was cast into meshes with different
concentrations of KGHK, and applied onto CAMs. After 24 hours, the preparations were removed, fixed, and sectioned. Transverse sections of the mesh
were stained with hematoxylin and eosin. Blood vessels are are indicated by arrows. Asterisks depict openings in the nylon mesh. (A) Vitrogen and PBS;
(B) KGHK, 0.01 mM; (C) KGHK, 0.5 mM; KGHK, 5 mat. Bar = 100 j.M. (Reprinted with permission from Molecular and Cellular Biology, 6:327—343,
1995, and Cliggott Publishing Co., [191).
Fig. 4. Distribution of SPARC in the CAM. (A) Camera lucida illustration of the vasculature in a day 10 CAM is divided into three zones that correspond
to regions of developmental age. Zone I contains the largest and developmentally oldest vessels. Zone III consists of the highest percentage of actively
growing vessels in the periphery. Zone II corresponds to the transitional region between the other two zones [19]. (B) Confocal analysis of a day 10 CAM
whole mount after staining with anti-SPARC peptide antibodies followed by FITC-conjugated secondary antibodies. Fluorescence intensity is translated
into a grey scale shown on the left. Highest concentrations of bound antibody are shown in red (+), and lowest concentrations are shown in violet (—).
Arrows indicate areas with high levels of expression of SPARC. (This figure is reprinted from a color graphic in [191; used with permission from
Molecular and Cellular Biology, 6:327—343, 1995, and Cliggott Publishing Co.).
17, 25, 261. Moreover, addition of SPARC to endothelial mono- with F-actin stabilizing agents protected against this SPARC-
layers in culture exhibiting tight cell-cell appositions without induced barrier dysfunction.
intercellular gaps resulted in a time-and concentration-dependent The spatial and temporal restriction of SPARC expression
increase in the transendothelial flux of 14C-BSA [28]. This effect during tissue remodeling, embryogenesis, and in response to
of SPARC was coincident with the redistribution of actin-contain- injury indicates an important role for this protein in normal
ing stress fibers since pretreatment of endothelial cell monolayers development [14, 30—33]. Microinjection of Xenopus embryos
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with antisense SPARC mRNA resulted in developmental defects
[34]. Overexpression of SPARC in muscle cells of C. elegans
resulted in an "uncoordinated" (Unc) phenotype, in which adults
moved abnormally or became paralyzed. In mice, the elevated
production of SPARC found in the gut, bone, and gonads, is
suggestive of a role in tissue remodeling, cell movement, and/or
proliferation in certain organs [30, 32].Recent ablation of SPARC
by gene targeting has resulted in viable animals that exhibit a
slower rate of dermal wound healing (C.C. Howe, P.W. Soballe,
A. Basu, A. Cesano, M.W. Xu, E.H. Sage, L.D. Thornburgh, S.
Samulewicz, unpublished observations) [35]. These results sup-
port a role for SPARC in modulation of cell-matrix interactions,
cell attachment, and/or synthesis and turnover of extracellular
matrix.
One of the most fundamental questions to be answered about
SPARC biology is: through which signal transduction pathway(s)
does SPARC mediate its counteradhesive and anti-proliferative
functions? Recent studies on cultured bovine endothelial cells
indicate that SPARC acts initially as a counteradhesive protein
through tyrosine phosphorylation-dependent pathways [36, 37].
Inhibitors of protein tyrosine kinases appear to protect against the
SPARC-induced changes in barrier function, actin rearrange-
ment, and changes in cell shape [36, 37]. Inhibition of cell cycle by
SPARC is believed to be a more distal effect and does not appear
to involve a tyrosine phosphorylation-dependent pathway [37; K.
Motamed, E.H. Sage, unpublished data]. Isolation of cell surface
receptor(s) for SPARC will undoubtedly provide a more precise
understanding of the exact mode of signaling by this matricellular
protein and help us achieve a more accurate understanding of its
involvement in specific stages of vascular development.
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